Recent Stem Cell Patient Treatments

Company recently treated a young girl who was severely brain damaged and basically catatonic who was told by doctors had very little chance for survival, and parents were told to consider removing the child's feeding tube. The company implanted nuro-stem cells and growth hormone into the child's spinal canal, and within a few weeks showed marked results. The child is now awake, sitting up, speaking, beginning to walk with the aid of braces, and now plans to attend pre-school.

Testimonials

Can read and see photos of recent testimonials from recent patients for stem cell treatment with Stem Cell Gene Nano. View Testimonials

Adult Stem Cells Treatment

Adult stem cells are in every organ of our body; heart, brain, lung, kidney, pancreas, spinal cord, eyes, gastrointestinal tract. They are essential in repair of injured and diseased tissues. However, in various injuries and disease the extent of the problem is overwhelming and insufficient numbers of adult stem cells cannot correct the problem.

A new form of treatment that the Company offers is that of administration of the patient’s own stem cells back into their body. The patient’s own blood sample (or in some cases) a sample of their bone marrow is sent to our laboratory The laboratory extracts out adult stem cells from this sample and expands them into millions of cells. Approximately a week later these are then sent back to the patient’s physician for administration. Patients may also have this procedure done at one of their treatment centers in California or Florida.

The Company considers the procedure safe since it involves the use of the patient’s own stem cells so that there is no problem with engraftment or rejection. The procedure should be considered for any major serious medical disorder or injury; also as part of an anti-aging medicine regime.

Patent Pending Stem Cell Lines

- Treatment for Diabetes
- Treatment for Parkinson's Disease
- Treatment for Retinal Blindness

About Stem Cell Gene Nano, Inc.

Based in Tampa, FL, Stem Cell Gene Nano, Inc. has been treating patients for the last four years for such serious chronic diseases including ALS, Alzheimer's, Parkinsonism, multiple sclerosis, autism, post stroke, brain damage, diabetes, heart disease, advanced kidney disease, COPD, scleroderma, lupus, rheumatoid arthritis, Crohn's, advanced cancer, transverse myeltis, etc. Along with these treatments the Company is currently filing patent applications for stem cell lines for the treatment for diabetes, Parkinson's disease, and retinal blindness. Stem Cell Gegenano is currently a privately held company with plans to take the Company public sometime in Q2 2009. For more information visit www.stemcellgenenano.com 

Anti-Aging Division

The Company will also begin selling anti-aging oral products for prevention of cardiac disease, lung disorders, diabetes and neurodegenerative diseases such as ALS, multiple sclerosis, Parkinsonism and Alzheimer's as well as anti-aging skin creams. The company plans to submit for patenting its protocol for pancreatic stem cells that produce insulin and its neuron stem cells that secrete dopamine.

-----------------

Investor Relations

Ludlow Capital Group, Inc.
Phone: (646) 670-6494
Email: info@ludlowcapital.com 

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated five hundred dollars for this investor presentation.